240 results about "Rotavirus RNA" patented technology

A packaging cell line capable of complementing recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary, diploid human cells (e.g., primary human retinoblasts, primary human embryonic kidney cells and primary human amniocytes) which are transformed by adenovirus E1 sequences either operatively linked on one DNA molecule or located on two separate DNA molecules, the sequences being operatively linked to regulatory sequences enabling transcription and translation of encoded proteins. Also disclosed is a cell line derived from PER.C6 (ECACC deposit number 96022940), which cell expresses functional Ad35 E1B sequences. The Ad35-E1B sequences are driven by the E1B promoter or a heterologous promoter and terminated by a heterologous poly-adenylation signal. The new cell lines are useful for producing recombinant adenoviruses designed for gene therapy and vaccination. The cell line can also be used for producing human recombinant therapeutic proteins such as human growth factors and human antibodies. In addition, the cell lines are useful for producing human viruses other than adenovirus such as influenza virus, herpes simplex virus, rotavirus, measles virus.

The invention discloses an infant milk power added with synbiotics, comprising the following components: fresh milk 40-68 gram; demineralized whey powder 15-34 gram; granulated sugar3-6 graml; vegetable oil 4-8 gram; compound prebiotics 0.4-20 gram; compound probiotic 1.0*10<5>-1.0*10<11> cfu. The inventive infant milk power can be ysed for building advantages of beneficial bacterium when a newborn infant starts colony valuation. Through adding probiotic, the number of probiotic is advanced to increase in a short time, through adding prebiotics having selectively increasing effect on probiotic, the added probiotic is performed with fast field setting, thereby maintaining advantages of probiotic in intestinal flora. The invention also markedly relieves diarrhoetic symptoms, and has definite treatment effect on diarrhea caused by rotavirus.

Therapeutic antimicrobial compositions and methods for providing enhanced immediate and residual anti-viral and antibacterial efficacy against rhinovirus, rotavirus, coronovirus, respitory syricytial virus, Gram-positive bacteria, Gram-negative bacteria and combinations thereof. More specifically, therapeutic antimicrobial compositions comprising an organic acid or organic acid mixture and a short-chain anionic surfactant having at least one of a large head group; a branched alkyl chain and an unsaturated alkyl chain, and therapeutic methods of use thereof.

The invention relates to a bacterial polysaccharide-protein conjugate vaccine with immunogenicity, in particular to a conjugate vaccine which is formed by connecting a recombinant rotavirus protein with a bacterial polysaccharide by using a covalent bond, a nucleotide sequence for coding the recombinant rotavirus protein, a recombinant expression system, a protein expressed by the recombinant expression system, a preparation method of the conjugate vaccine and a pneumococcus polysaccharide-recombinant rotavirus protein conjugate vaccine. The bacterial polysaccharide is connected with a recombinant rotavirus surface protein through a covalent bond. The recombinant rotavirus protein is selected from a partial or complete amino acid sequence of a P-gene rotavirus protein and a partial or complete amino acid sequence of a G-gene rotavirus protein.

The invention provides a method for preparing triple vaccine for preventing porcine transmissible gastroenteritis, porcine epidemic diarrhea and porcine rotavirus. The method comprises the following steps: inoculating a host-cell line with a 90 percent grown monostratum against a porcine transmissible gastroenteritis virus, a porcine epidemic diarrhea virus and a porcine rotavirus respectively, and adding a cell maintenance media into the host-cell lines respectively to be cultured at 37 DEG C; after cytopathic effect reaches over 75 percent, collecting viruses to be stored at 20 DEG C below zero for standby; mixing the viruses according to 10 TCID50 in 1:1:1, and simultaneously adding Freund's complete adjuvant and immunopotentiator into the mixture to inactivate the mixture by formaldehyde at 37 DEG C for 24 hours; and adding an oil adjuvant into the mixture to prepare a vaccine of water-oil-water preparation. The method can be used for preparing the triple vaccine for preventing the porcine transmissible gastroenteritis, the porcine epidemic diarrhea and the porcine rotavirus so as to solve the problem that the diseases do not have an effective medicine to treat currently.

The present invention is directed to the generation and use of recombinant rotavirus fusion proteins as immunogens to produce a protective immune response from immunized individuals. In one embodiment, the present invention contemplates a recombinant rotavirus fusion protein vaccine composition comprising a rotavirus subunit protein or immunogenic fragment thereof, and an adjuvant in combination with the recombinant rotavirus subunit fusion protein. In one aspect of this embodiment, the recombinant rotavirus fusion protein comprises a rotavirus subunit protein and a fusion partner protein in genetic association with the rotavirus subunit protein, wherein the fusion partner protein does not interfere with expression and immunogenicity of the rotavirus subunit protein, the fusion partner protein prevents complex formation by the rotavirus subunit protein, and the fusion partner protein facilitates purification of the recombinant rotavirus fusion protein. In another aspect of this embodiment, the rotavirus subunit protein is selected from the group consisting of VP1, VP2, VP3, VP4, VP6, VP7, NSP1, NSP2, NSP3, NSP4 or NSP5. In yet another aspect of this embodiment, the rotavirus subunit protein is VP6.

The invention provides a triple live vaccine for a swine transmissible gastroenteritis virus, a swine epidemic diarrhea virus and a swine rotavirus and a preparation method thereof. The content of the three viruses is not less than 107.5 TCID50 (Tissue Culture Infectious Dose 50)/mL, and the volume ratio is 1:1:1. The triple live vaccine provided by the invention solves the problem that a multiple vaccine for effectively preventing and treating such three diseases as swine transmissible gastroenteritis, swine epidemic diarrhea and the swine rotavirus is not available on the current market, and especially realizes the prevention and control on the swine rotavirus. Compared with the existing method of inoculating with three simplex vaccines to prevent such three transmissible diseases, the triple live vaccine provided by the invention is economical to use, simplifies the immunization procedure and lowers the epidemic prevention cost, thereby providing a new simple and convenient immunization way for farms in China.

The invention discloses a kit and oligonucleotide sequences for detecting rotavirus A, in particular to a group of oligonucleotides which are used for detecting rotavirus A and have the oligonucleotide sequences shown from the sequence table SEQ ID No.1 to the sequence table SEQ ID No.5, the kit containing the oligonucleotides and a detection method thereof. The kit of the invention has high sensitivity, strong specificity, low cost and simple and convenient operation. During detection, when lots of nucleic acid is synthesized, a by-product magnesium pyrophosphate precipitate is generated, which has high specificity. Whether the products are amplified or not can be judged only by observing the turbidity of the products with naked eyes.

The present invention relates to novel recombinant polypeptide antigens that may comprise subunit vaccines against rotavirus infection. Further, the present invention relates to methods for use of said antigens in the diagnosis, treatment and prevention of rotavirus infection.

The invention provides a primer, a probe and a kit for detecting rotavirus and Norovirus liquid phase chips. The primer comprises three pairs of primers of a specific amplification A type rotavirus sequence, a GI type Norovirus sequence and a GII type Norovirus sequence. The probe comprises three specificity detection probes of A type rotavirus, GI type Norovirus and GII type Norovirus. The kit comprises the three pair of primers and a specificity detection microsphere mixture prepared by coupling the three specificity detection probes and a fluorescence coding microsphere. The experiment proves that the primer and the probe disclosed by the invention are characterized in that a method of combining multiple PCR (polymerase chain reaction) with liquid phase chip detection can simultaneously and accurately detect the A type rotavirus, the GI type Norovirus and the GII type Norovirus. The primer, the probe and the kit have the advantages of strong specificity and high sensitivity.

The present invetnion refers to the use of rotavirus proteins VP4, VP8 and their derived fusion proteins and peptides, for enhancing the delivery of pharmaceutical agents through the paracellular pathway. These rotavirus proteins and derived peptides may additionally be employed to reduce unwanted cellular adhesion that can occur between cancerous cells, or between normal cells as a result of surgery, injury, chemotherapy, disease, inflammation or other pathological conditions.

The present invention discloses preparation process of inactivated rotavirus vaccine. Rotavirus strains G1, G2, G3 and G4 are made to adapt human diploid cell line and propagate on human diploid cell line to obtain the producing strain of inactivated rotavirus vaccine, with the human diploid cell line being KMB17. The human diploid cell line used as the cell matrix for producing inactivated rotavirus vaccine is safer compared with available cell matrixes. Therefore, by means of the established technological platform, it is possible to develop inactivated rotavirus vaccine with other serotypes of rotavirus as the target.

The present invention relates to a Lactobacillus reuteri variant from animal sources that inhibits rotavirus infection and other pathogenic microorganisms, as well as being tolerant of gastric and bile acids. Also, this invention relates to a prophylactic and therapeutic composition comprising the same for contributing in many probiotic ways to the host's general health and preventing and treating diseases or conditions associated with rotavirus and other enteric pathogens.

The invention relates to human rotavirus Delta VP8* subunit recombinant protein and application thereof. The human rotavirus Delta VP8* subunit recombinant protein comprises a T cell epitope P2 in tetanus toxin and a rotavirus Delta VP8* subunit. By the recombinant protein disclosed by the invention, the immune efficacy of a Delta VP8* subunit vaccine can be greatly improved; faster and stronger neutralization antibody titer can be induced; moreover, anti-p[4] genotype specific rotavirus cross neutralization antibody of high titer can be induced; simultaneously, the potential risk of inducing intussusception by taking attenuated rotavirus vaccine orally can be overcome; therefore, the recombinant protein is applicable to preparing a rotavirus vaccine.

The invention provides a method for preparing a rotavirus vaccine stock solution by using serum-free Vero cells. The method comprises the following steps: culturing Vero cells by using a serum-free culture medium, thus obtaining serum-free culture medium adapted cell strains; establishing a serum-free Vero cell seed bank by utilizing the obtained serum-free culture medium adapted cell strains; establishing a serum-free rotavirus strain working seed bank by utilizing the obtained serum-free culture medium adapted cell strains; carrying out reviving, culturing, passage and amplification on cells in a Vero cell working seed bank by utilizing the serum-free culture medium, using the cells in the Vero cell working seed bank as basic cells cultured in a bioreactor, and carrying out continuous perfusion culture on high-density Vero cells by applying the bioreactor and a microcarrier and using the serum-free culture medium after cell amplification; after inoculating virus seeds in the rotavirus strain working seed bank, carrying out bioreactor-microcarrier serum-free culture, obtaining a virus solution when virus is amplified to the summit, obtaining liquid virus titer, and carrying out clarification and ultra-filtration concentration, thus obtaining a serum-free rotavirus stock solution for human.

The invention belongs to the field of biological gene, disclosing the recombination and expression of a rotavirus Vp6 gene and Bacterium acidi lactic nonresistance expression vector and it is characterized in: digesting the cloning vector and vector taking thyA gene as a selection pressure using Sac I and KpnI, purifying and recovering, linking the products with T4 DNA ligase, transforming to thyA gene-deficient E. coli competence E. coli X13, culturing in the medium, and screening to obtain prokaryotic recombinant expression plasmid through growing functional redeem, inducing positive bacteria for expression using threonine to obtain high expression of the recombinant plasmid. Molecular weight of fusion protein is about 44.88 KD. Beneficial effects are: VP6 protein is RV-group-specific antigen, locating at the virus endoconch, occupying 51%of the virus particles. As VP6 mainly stimulates organism to generate mucosal immune antibody sIgA, it plays a very important role in the mucosal immune, thus advanced development of rotavirus Vp6 mediated gene oral mucosal immune genetically engineered vaccine has important significance.

The invention is applicable to the technical field of biotechnology and medical detection and provides a diarrhea virus detection kit and method. The detection kit comprises PCR (polymerase chain reaction) liquid which comprises a PCR buffer solution, MgCl2, dNTP, DNA polymerase, primer pairs, probe sequences and Homo-tag, wherein the primer pairs and the probe sequences respectively aim at type I, type II and type IV of sapovirus, type I and type II of norovirus, rotavirus, adenovirus and astrovirus, the 5' ends of the probe sequences are connected with fluorophore, and the 3' ends of the probe sequences are connected with quencher. The detection kit provided by the invention can detect seven viruses (subtype) related to diarrhea at one time, and compared with a detection method in the prior art, the detection method provided by the invention has the advantages that operation is simple and convenient, a result is quick to read, and false positive is avoided.

The invention relates to a reagent kit for detecting rotavirus nucleic acid, in particular to a reagent kit for detecting rotavirus nucleic acid by using a fluorescence PCR technique. The reagent kitcan be used for qualitatively detecting the rotavirus nucleic acid. Due to the characteristics of high sensitivity, high specificity, simple operation and high detecting speed, the reagent kit can bewidely used for the auxiliary diagnosis of rotavirus infections.

The present invention provides vaccine compositions of attenuated human rotavirus. More particularly, the attenuated human rotavirus is produced by cold passage and thus contains attenuating mutations which produce virus having a cold-adapted (ca) and temperature sensitive (ts) phenotype. The attenuated strains are used in methods for stimulating the immune system of an individual to induce protection against human rotavirus by administration of the ca attenuated rotavirus.

The invention relates to nucleic acid composition and a kit for detecting diarrhea viruses as well as a use method of the kit. The nucleic acid composition for detecting diarrhea viruses comprises anamplification primer pair and detection probes corresponding to amplification primers. The nucleic acid composition for detecting diarrhea viruses can at least detect three of group A rotavirus, groupB rotavirus, group C rotavirus, norovirus, norovirus I type, norovirus II type, sapovirus, astrovirus and adenovirus simultaneously and has high detection sensitivity and good specificity.